Serum vitamin D3 levels are not associated with thyroid cancer prevalence in euthyroid subjects without autoimmune thyroid disease

Korean Journal of Internal Medicine

Volumn 32, Issue 1, 2017, Pages 102-108

  Choi, Yun Mi ^a   Kim, Won Gu ^a   Kim, Tae Yong ^a   Bae, Sung Jin ^a   Kim, Hong Kyu ^a   Jang, Eun Kyung ^a   Jeon, Min Ji ^a   Han, Ji Min ^b   Shong, Young Kee ^a   Kim, Won Bae ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Thyroid autoimmunity; Thyroid neoplasms; Vitamin D

Indexed keywords

CALCIFEDIOL; THYROID PEROXIDASE ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; THYROID HORMONE; THYROID MICROSOMAL ANTIBODIES;

ADULT; ARTICLE; AUTOIMMUNE THYROIDITIS; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; EUTHYROIDISM; EVALUATION STUDY; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREVALENCE; SEASONAL VARIATION; SEX DIFFERENCE; THYROID CANCER; VITAMIN BLOOD LEVEL; AGED; BLOOD; CASE CONTROL STUDY; DIAGNOSTIC IMAGING; RISK FACTOR; SEASON; SOUTH KOREA; THYROID NEOPLASMS; TIME FACTOR; VITAMIN D DEFICIENCY;

ADULT; AGED; AUTOANTIBODIES; BIOMARKERS; BIOPSY, FINE-NEEDLE; CALCIFEDIOL; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; SEASONS; SEOUL; THYROID HORMONES; THYROID NEOPLASMS; TIME FACTORS; ULTRASONOGRAPHY; VITAMIN D DEFICIENCY;

EID: 85009448123     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2015.090     Document Type: Article

References (37)

1. Rosen CJ, Adams JS, Bikle DD, et al. The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev 2012;33:456-492.
2. Wolden-Kirk H, Gysemans C, Verstuyf A, Mathieu C. Extraskeletal effects of vitamin D. Endocrinol Metab Clin North Am 2012;41:571-594.
3. Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health 2006;96:252-261.
4. Holick MF. Vitamin D: its role in cancer prevention and treatment. Prog Biophys Mol Biol 2006;92:49-59.
5. Cheung FS, Lovicu FJ, Reichardt JK. Current progress in using vitamin D and its analogs for cancer prevention and treatment. Expert Rev Anticancer Ther 2012;12:811-837.
6. Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:827-838.
7. Krishnan AV, Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 2011;51:311-336.
8. Clinckspoor I, Verlinden L, Mathieu C, Bouillon R, Verstuyf A, Decallonne B. Vitamin D in thyroid tumorigenesis and development. Prog Histochem Cytochem 2013;48:65-98.
9. Dackiw AP, Ezzat S, Huang P, Liu W, Asa SL. Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer. Endocrinology 2004;145:5840-5846.
10. Liu W, Asa SL, Fantus IG, Walfish PG, Ezzat S. Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/ akt-dependent and -independent pathways. Am J Pathol 2002;160:511-519.
11. Balla B, Kosa JP, Tobias B, et al. Marked increase in CY-P24A1 gene expression in human papillary thyroid cancer. Thyroid 2011;21:459-460.
12. Roskies M, Dolev Y, Caglar D, et al. Vitamin D deficiency as a potentially modifiable risk factor for thyroid cancer. J Otolaryngol Head Neck Surg 2012;41:160-163.
13. Penna-Martinez M, Ramos-Lopez E, Stern J, et al. Vitamin D receptor polymorphisms in differentiated thyroid carcinoma. Thyroid 2009;19:623-628.
14. Stepien T, Krupinski R, Sopinski J, et al. Decreased 1-25 dihydroxyvitamin D3 concentration in peripheral blood serum of patients with thyroid cancer. Arch Med Res 2010;41:190-194.
15. Sahin M, Ucan B, Ginis Z, et al. Vitamin D3 levels and insulin resistance in papillary thyroid cancer patients. Med Oncol 2013;30:589.
16. Laney N, Meza J, Lyden E, Erickson J, Treude K, Goldner W. The prevalence of vitamin D deficiency is similar between thyroid nodule and thyroid cancer patients. Int J Endocrinol 2010;2010:805716.
17. Jonklaas J, Danielsen M, Wang H. A pilot study of serum selenium, vitamin D, and thyrotropin concentrations in patients with thyroid cancer. Thyroid 2013;23:1079-1086.
18. Zhang LR, Sawka AM, Adams L, Hatfield N, Hung RJ. Vitamin and mineral supplements and thyroid cancer: a systematic review. Eur J Cancer Prev 2013;22:158-168.
19. Boi F, Minerba L, Lai ML, et al. Both thyroid autoimmunity and increased serum TSH are independent risk factors for malignancy in patients with thyroid nodules. J Endocrinol Invest 2013;36:313-320.
20. Fiore E, Rago T, Latrofa F, et al. Hashimoto’s thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer 2011;18:429-437.
21. Wu X, Lun Y, Jiang H, et al. Coexistence of thyroglobulin antibodies and thyroid peroxidase antibodies correlates with elevated thyroid-stimulating hormone level and advanced tumor stage of papillary thyroid cancer. Endocrine 2014;46:554-560.
22. Fiore E, Vitti P. Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease. J Clin Endocrinol Metab 2012;97:1134-1145.
23. Paparodis R, Imam S, Todorova-Koteva K, Staii A, Jaume JC. Hashimoto’s thyroiditis pathology and risk for thyroid cancer. Thyroid 2014;24:1107-1114.
24. Jankovic B, Le KT, Hershman JM. Clinical review: Hashimoto’s thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metab 2013;98:474-482.
25. Choi YM, Kim WG, Kim TY, et al. Low levels of serum vitamin D3 are associated with autoimmune thyroid disease in pre-menopausal women. Thyroid 2014;24:655-661.
26. Choi HS, Oh HJ, Choi H, et al. Vitamin D insufficiency in Korea: a greater threat to younger generation: the Korea National Health and Nutrition Examination Survey (KNHANES) 2008. J Clin Endocrinol Metab 2011;96:643-651.
27. Rosen CJ. Clinical practice: vitamin D insufficiency. N Engl J Med 2011;364:248-254.
28. Han JM, Kim TY, Jeon MJ, et al. Obesity is a risk factor for thyroid cancer in a large, ultrasonographically screened population. Eur J Endocrinol 2013;168:879-886.
29. Manson JE, Mayne ST, Clinton SK. Vitamin D and prevention of cancer: ready for prime time? N Engl J Med 2011;364:1385-1387.
30. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
31. Kweon SS, Shin MH, Chung IJ, Kim YJ, Choi JS. Thyroid cancer is the most common cancer in women, based on the data from population-based cancer registries, South Korea. Jpn J Clin Oncol 2013;43:1039-1046.
32. Li N, Du XL, Reitzel LR, Xu L, Sturgis EM. Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980-2008. Thyroid 2013;23:103-110.
33. Kim TY, Kim WG, Kim WB, Shong YK. Current status and future perspectives in differentiated thyroid cancer. Endocrinol Metab (Seoul) 2014;29:217-225.
34. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-281.
35. Choi HS. Vitamin D status in Korea. Endocrinol Metab (Seoul) 2013;28:12-16.
36. Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA, et al. Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010;172:81-93.
37. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol 2009;19:73-78.